Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma.
3 contributing indexes 4 score components composite score.
Canonical asset packet first: fundamentals, macro index exposure, entry value, and active narrative alignment. Driver rows link back to the public index that moved the score.
| Index | Driver | Reason | Weight | Condition | Contribution | As Of |
|---|---|---|---|---|---|---|
| RQRI | Risk-Quality Rotation Index | risk appetite | 4% | risk appetite — tailwind Moderate signal—/100Tailwind +1.30σ | +0.034 | 2026-05-22 |
| BPHI | Biotech & Pharma Health Index | biologics innovation | 18% | biologics innovation — tailwind Near normal—/100Tailwind +0.13σ | +0.033 | 2026-05-22 |
| RACI | Robotics & Automation Capex Index | research activity | 5% | research activity — tailwind Moderate signal—/100Tailwind +0.53σ | +0.030 | 2026-05-22 |
